NCT04832724 - RGX-314 Gene Therapy Pharmacodynamic Study for Neovascular Age-related Macular Degeneration (nAMD) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 22, 2021

Primary Completion Date

October 2, 2023

Study Completion Date

March 18, 2024

Conditions

Neovascular Age-related Macular DegenerationWet Macular DegenerationWet Age-related Macular Degeneration

Interventions

GENETIC

RGX-314

RGX-314 is a recombinant adeno-associated virus gene therapy vector carrying a coding sequence for a soluble anti-VEGF protein

Trial Locations (13)

Wills Eye Hospital, Philadelphia

Wilmer Eye Institute, Baltimore

Retina Vitreous Associates of Florida, St. Petersburg

Charles Retina Institute, Germantown

Texas Retina Associates, Dallas

Retina Consultants of Texas, The Woodlands

Retinal Consultants of Arizona, Phoenix

Barnet Dulaney Perkins Eye Center, Sun City

Eye Associates of New Mexico, Albuquerque

Sierra Eye Associates, Reno

Retina Consultants of San Diego, San Diego

California Retina Consultants, Santa Barbara

Ophthalmic Consultants of Boston, Boston